India, Aug. 7 -- This week's biotech roundup captured a mix of regulatory wins, restructuring action, and deal momentum driving sector sentiment. FDA and EU approvals spanned oncology, vaccines and rare disease, while layoffs and cost-saving measures underscored operational tightening across the sector. Strategic acquisitions and licensing agreements advanced pipeline diversification, and clinical trial updates delivered both progress and setbacks in Parkinson's, obesity, and endometrial cancer, reflecting the industry's dynamic balance between innovation and volatility.
Read on...
FDA and EC Approvals
Replimune's TUDRIQEV Wins FDA Nod
Replimune Group, Inc. (REPL) secured FDA approval for its oncolytic immunotherapy TUDRIQEV (vusolimoge...